Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV002958775 | SCV003280965 | uncertain significance | Emery-Dreifuss muscular dystrophy 5, autosomal dominant | 2022-03-26 | criteria provided, single submitter | clinical testing | This variant is not present in population databases (gnomAD no frequency). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function output the following: SIFT: "Tolerated"; PolyPhen-2: "Possibly Damaging"; Align-GVGD: "Class C0". The lysine amino acid residue is found in multiple mammalian species, which suggests that this missense change does not adversely affect protein function. This variant has not been reported in the literature in individuals affected with SYNE2-related conditions. This sequence change replaces glutamic acid, which is acidic and polar, with lysine, which is basic and polar, at codon 3549 of the SYNE2 protein (p.Glu3549Lys). |
Ambry Genetics | RCV004877767 | SCV005510977 | uncertain significance | not specified | 2024-09-30 | criteria provided, single submitter | clinical testing | The c.10645G>A (p.E3549K) alteration is located in exon 52 (coding exon 51) of the SYNE2 gene. This alteration results from a G to A substitution at nucleotide position 10645, causing the glutamic acid (E) at amino acid position 3549 to be replaced by a lysine (K). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |